Table 1.
Cytotoxicity of CYB-L10 against NCI60 cell lines.
| Panel | Cell line | GI50 (μM)a | Panel | Cell line | GI50 (μM) |
|---|---|---|---|---|---|
| MGMb | 0.050 | Colon cancer | COLO 205 | 0.137 | |
| Leukemia | CCRF-CEM | 0.379 | HCC-2998 | 0.252 | |
| HL-60 (TB) | 0.24 | HCT116 | 0.0417 | ||
| K-562 | 0.0282 | HCT-15 | 0.0395 | ||
| MOLT-4 | 0.217 | HT29 | 0.58 | ||
| RPMI-8226 | 0.166 | KM12 | 0.168 | ||
| SR | <0.01 | SW-620 | <0.01 | ||
| Non-small cell lung cancer | A549/ATCC | 0.0205 | Renal cancer | 786-0 | 0.029 |
| EKVX | 1.36 | A498 | 0.0343 | ||
| HOP-62 | <0.01 | ACHN | <0.01 | ||
| NCI-H226 | 0.0289 | CAKI-1 | 0.0339 | ||
| NCI-H23 | <0.01 | RXF 393 | 0.0351 | ||
| NCI-H322M | 0.0977 | SN 12C | <0.01 | ||
| NCI-H460 | <0.01 | TK-10 | 0.361 | ||
| NCI-H522 | 0.0119 | UO-31 | 0.013 | ||
| CNS cancer | SF-268 | 0.0185 | Breast cancer | MCF7 | <0.01 |
| SF-295 | 0.0257 | MDA-MB-231/ATCC | 1.62 | ||
| SF-539 | <0.01 | HS 578T | 0.0369 | ||
| SNB-19 | <0.01 | BT-549 | 0.0558 | ||
| SNB-75 | <0.01 | T-47D | 0.961 | ||
| U251 | 0.0109 | MDA-MB-468 | 1.82 | ||
| Melanoma | LOX IMVI | <0.01 | Ovarian cancer | IGROV1 | 0.0462 |
| MALME-3M | 0.045 | OVCAR-3 | 0.17 | ||
| M14 | <0.01 | OVCAR-4 | 1.22 | ||
| MDA-MB-435 | 0.0646 | OVCAR-5 | 0.648 | ||
| SK-MEL-2 | 0.0462 | OVCAR-8 | 0.0281 | ||
| SK-MEL-28 | 0.0546 | NCI/ADR-RES | 0.0368 | ||
| SK-MEL-5 | 0.0285 | SK-OV-3 | <0.01 | ||
| UACC-257 | 0.0546 | Prostate cancer | PC-3 | 0.19 | |
| UACC-62 | <0.01 | DU-145 | 0.0305 |
a
GI50 values were defined as the concentrations of compounds that resulted in 50% cell growth inhibition. The cells were incubated for 2 days with the tested compounds.
b
MGM: mean graph midpoint for growth inhibition of all human cancer cell lines.